Articles by Daniel Marsh
MercadoLibre Gains Despite JPMorgan Target Cut Amid Brazil Margin Concerns
MercadoLibre stock edged higher Monday, shrugging off a price target reduction by JPMorgan, which maintained an Overweight rating but flagged competitive margin pressures in Brazil.
MercadoLibre Gains Despite JPMorgan Target Cut Amid Brazil Margin Concerns
MercadoLibre stock advanced 0.9% to $1,773.22 Monday, even as JPMorgan reduced its price target to $2,650, highlighting competitive margin pressures in Brazil. Investors are monitoring inflation and upcoming corporate events.
Travel Stocks Slide on Geopolitical Tensions, Oil Spike
Booking Holdings shares fell alongside the broader travel sector Monday, pressured by surging oil prices and widespread flight cancellations linked to Middle East tensions. The company's 25-for-1 stock split is scheduled for early April.
Travel Stocks Lose $22.6B as Oil Spike, Flight Cancellations Mount
Booking Holdings declined 0.7% as the broader travel sector shed $22.6 billion in market value. The selloff was driven by a 13% spike in oil prices and major flight disruptions linked to Middle East conflict.
AeroVironment Plunges on Downgrade Amid SCAR Contract Uncertainty
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform, driven by uncertainty over a key U.S. Space Force contract.
AeroVironment Plummets on SCAR Contract Uncertainty, Raymond James Downgrade
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform. The broker highlighted uncertainty surrounding the U.S. Space Force's $1.4 billion SCAR satellite-communications contract.
Lilly Shares Slip Amid China Drug Approval, Focus on Obesity Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 Monday despite broader market gains. The dip came as Innovent Biologics secured Chinese regulatory clearance for the cancer therapy Jaypirca, a drug developed with Lilly.
Lilly Shares Dip Amid Sector Weakness, Focus on Obesity Drug Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 on Monday, underperforming the broader market. The focus remains on the company's obesity drug pipeline and an upcoming FDA review for its oral GLP-1 candidate, orforglipron.
AES Plunges 17% on $15 Takeover Bid as Market Prices in Deal Risk
AES Corp shares fell sharply after the power company agreed to a $15-per-share buyout. The stock traded below the offer price as investors weighed a lengthy closing timeline and regulatory hurdles.
AES Plunges 17% as $15 Buyout Deal Faces Scrutiny Over Timeline, Risk
Shares of AES Corp. tumbled 17% Monday after the power company agreed to a $15-per-share buyout, trading below the offer price as investors weigh a lengthy closing timeline and regulatory risks.
ISM Price Surge Stirs Inflation Fears as Stocks Await Jobs Data
Manufacturing input costs surged to their highest level since October 2022, according to the ISM report, while the S&P 500 ended nearly flat. Investors are now focused on key labor market data due later this week.